Ajanta Pharma has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility at Paithan, Maharashtra. The inspection has been classified as Voluntary Action Indicated (VAI).
The current Good Manufacturing Practices (cGMP) inspection of the Paithan facility was conducted by the USFDA from April 13, 2026 to April 21, 2026.
Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.
